As per our report, the size of the Latin American Clinical Trials Market has been estimated at USD 1.72 Billion in 2020 and is projected to reach USD 2.55 Billion by 2025 at a CAGR of 8.20% from 2020 to 2025.
Complexities and volumes of data are constantly increasing in clinical trials. As the cost of development break records and patent cliffs approach, there is an urgent need for pharmaceutical companies to raise R&D efforts. Cloud and analytics convergence is omnipresent, and systematic improvements are being made in the clinical trial phase by digital technologies. Healthcare models are witnessing tectonic shifts and seeing a large inflow of new models of clinical trials that are structured, standardized, and foster patient interest. Drug companies are pushing the boundaries of R&D initiatives to improvise their models of clinical trials that will help them cope with ever-increasing development costs. For pharmaceutical and medical device firms, speedier clinical trials are crucial as they are time and capital intensive.
MARKET DRIVERS
One of the critical factors that can be related to the growth of clinical research in Latin America is their ability to meet the requirements for subject enrolment, particularly as the need for more subjects and greater diversity of patients is increasing. In addition, retention rates are generally twice in Latin America than in Western Europe, and significantly higher than in the United States and Canada. The key drivers of the clinical trial industry in LATAM usually involve rising disease prevalence, high pharmaceutical industry R&D expenditure, and growth in new treatments such as personalized medicine that supports market growth.
Regulatory systems, however, continue to evolve, and differences between different populations of patients pose ethical problems. Last but not least, there is a need to address substantial variations in regional Spanish and cultural differences among ethnic minority communities, particularly in the preparation of patient services. Some groups of patients may have reduced readability and low economic status. Specific measures need to be taken in such situations to ensure patient rights are protected.
This report on Europe Clinical Trails Market has been segmented into the following categories:
Geographically, the Clinical Trials market in the Latin America region is proceeding with a high CAGR. Emerging market destinations in Latin America are attractive because of the opportunity to collect data from patients with diverse ethnic backgrounds, as well as the availability of qualified investigators, all without the competition or cost they face in more developed nations.
In Brazil, the new clinical studies lift up safety concerns about coronavirus patients that they are taking a high dose of chloroquine drug of Malaria. Brazil’s Techtrials Partnered with TriNetX healthcare organization which have 64 million patients database over the country. It covers 90% of the Brazilian population having various diseases, and it is beneficial for the institutes to take clinical trials on various diseases by knowing the availability of participants. This is the major factor responsible for the growth of the clinical trials market in Brazil. The data of patients available gives the current idea about active corona patients to treat them wisely by focusing on the research. The going on research and development to find this vaccine will give a chance to Brazil clinical trial market to set their position worldwide.
Major companies operating in the Latin America Clinical Trails Market profiled in this report are Chiltern, Omnicare, PPD, Parexel, Kendle, Quintles, ICON Plc, and Charles River.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Phases
5.1.1 Introduction
5.1.2 Phase I
5.1.3 Phase II
5.1.4 Phase III
5.1.5 Y-o-Y Growth Analysis, By Phases
5.1.6 Market Attractiveness Analysis, By Phases
5.1.7 Market Share Analysis, By Phases
5.2 Design
5.2.1 Introduction
5.2.2 Interventional trials
5.2.3 Observational trials
5.2.4 Expanded Access trials
5.2.5 Y-o-Y Growth Analysis, By Design
5.2.6 Market Attractiveness Analysis, By Design
5.2.7 Market Share Analysis, By Design
5.3 Indications
5.3.1 Introduction
5.3.2 Autoimmune
5.3.3 Blood disorders
5.3.4 Cancer
5.3.5 Circulatory
5.3.6 CNS
5.3.7 Congenital
5.3.8 CVS
5.3.9 Dermatology
5.3.10 Ear
5.3.11 Gastrointestinal
5.3.12 Genitourinary
5.3.13 Infections
5.3.14 Mental disorders
5.3.15 Metabolic
5.3.16 Musculoskeletal
5.3.17 Nose
5.3.18 Ophthalmology
5.3.19 Y-o-Y Growth Analysis, By Indications
5.3.20 Market Attractiveness Analysis, By Indications
5.3.21 Market Share Analysis, By Indications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Phase
6.1.3.3 By Design
6.1.3.4 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Phase
6.1.4.3 By Design
6.1.4.4 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Phase
6.1.5.3 By Design
6.1.5.4 By Indication
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Chiltern
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Omnicare
8.3 PPD
8.4 Parexel
8.5 Kendle
8.6 Quintles
8.7 ICON Plc
8.8 Charles River
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
